CRISPR: Rewriting the Code of Life

The two decisions we are making by accident

Could a harmful gene ever simply be corrected? For most of medical history the answer was no, you inherited what you inherited. Today, scientists are doing exactly that. In December 2023 the U.S. Food and Drug Administration approved Casgevy, the first medicine built from CRISPR, to treat sickle cell disease (BioPharma Dive, 2023). CRISPR is often described as a biological “cut and paste” system, but that phrase hides the real story. The tool did not arrive as a product; it emerged from decades of curiosity-driven research, and it now forces two choices on us that we are, so far, making largely by accident.

This paper argues that the science of CRISPR is no longer the hard part, the governance is. Two decisions will shape whether this technology heals or divides us. First, whether the world permits heritable (germline) editing, changes passed to every future generation, and enforces that decision rather than merely disapproving of it. Second, whether cures like Casgevy reach the people who actually carry these diseases, or whether a $2.2-million price tag turns a medical breakthrough into a new genetic divide. History and mechanism, below, explain how we got this power; the argument is about what we owe the people it could help or harm.

How curiosity became a tool

CRISPR began as a mystery, not a mission. In 1987, researchers at Osaka University noticed strange repeated sequences in bacterial DNA without knowing their purpose (Ishino et al., 1987). In 2002 the pattern was named CRISPR (Jansen et al., 2002), and by 2005 Francisco Mojica and colleagues proposed that it was part of a bacterial immune system, a genetic “memory” of past viral attacks (Mojica et al., 2005). The turning point came in 2012, when Jennifer Doudna and Emmanuelle Charpentier showed that this system could be programmed to cut any chosen DNA sequence (Jinek et al., 2012). Eight years later they shared the 2020 Nobel Prize in Chemistry for it. The lesson worth keeping is that the most powerful tool in modern biology came from scientists asking what a repeated sequence was for, which is exactly why governance cannot be an afterthought bolted on at the end.

How CRISPR works

At its core, CRISPR-Cas9 has two parts: the Cas9 protein, which acts like molecular scissors, and a guide RNA, which works like a GPS that steers those scissors to one exact address in the three-billion-letter genome. Once there, Cas9 cuts the DNA. The cell then repairs the break in one of two ways: a quick, error-prone repair that can switch a gene off, or a precise repair that can paste in a corrected sequence. This is the difference that matters for the argument. Editing the cells of one living patient, somatic editing, as in Casgevy, affects only that person. Editing an embryo, egg or sperm, germline editing, rewrites every cell of a future person and all of their descendants. Same tool; two completely different moral situations.

The cure is real, and so is the price

Sickle cell disease is the ideal test case because CRISPR now genuinely works against it. In the exa-cel (Casgevy) trial, 29 of 30 evaluable patients, 96.7%, were free of severe pain crises for at least 12 consecutive months, and all of them avoided hospitalization for those crises over the same period (Children's Hospital of Philadelphia / NEJM, 2024). The therapy works by switching a genetic control so that patients make protective fetal hemoglobin again. For a disease defined by unpredictable, agonizing crises, this is close to a functional cure.

The stakes are large. About 515,000 babies were born with sickle cell disease in 2021, and roughly 7.74 million people were living with it worldwide, a 41% rise since 2000, with an estimated 376,000 SCD-related deaths that year (The Lancet Haematology, 2023). The burden is concentrated in sub-Saharan Africa and India, not in the wealthy health systems where Casgevy is sold. And Casgevy costs about $2.2 million per patient (BioPharma Dive, 2023). A one-time cure that only the richest health systems can buy does not close the health gap between rich and poor, it risks widening it into a biological one.

India makes the equity problem concrete. Sickle cell disease is most common in the country's tribal populations, and in 2023 the government launched the National Sickle Cell Anaemia Elimination Mission, aiming to screen 7 crore (70 million) people and to eliminate the disease as a public-health problem before 2047 (National Health Mission, 2023). India has already built the hardest part of access, the screening and counselling infrastructure to find patients. What it cannot do is pay $2.2 million per person. So the same technology that offers a cure also poses a question no lab can answer: a cure for whom?

The germline line, and why norms alone failed

CRISPR's other danger is not price but permanence. In 2018 the Chinese scientist He Jiankui used CRISPR to edit the CCR5 gene in embryos, and twin girls were born with heritable changes they never consented to and that offered no clear benefit. The world's scientists condemned it, and it happened anyway. He was later sentenced to three years in prison and fined 3 million yuan (about $430,000) for illegal medical practice (CBS News, 2019). The episode proved that disapproval is not a safeguard. It also exposed the risk the paper calls ethics shopping: because rules differ from country to country, high-risk work migrates to wherever oversight is weakest.

Responses exist, but they are incomplete. In 2019, Eric Lander, Françoise Baylis and colleagues called in Nature for a global moratorium on clinical germline editing, a framework in which nations voluntarily commit not to approve any clinical germline edit unless strict conditions are met, for an initial period of about five years, while still allowing laboratory research and somatic therapies (Lander et al., Nature, 2019). In 2021 the WHO published recommendations and a governance framework that included a registry of all human-genome-editing research and a confidential channel to report illegal or unregistered work (WHO, 2021). These are the right ideas. Their weakness is that “voluntary” and “recommend” have no teeth, which is exactly why He Jiankui was a warning, not an aberration.

What to actually do

1. Turn the moratorium into an enforceable gate, not a request. A voluntary commitment only works if defection is expensive. Three real chokepoints can supply the teeth without a new global treaty. First, make the WHO registry mandatory in practice: leading medical journals and scientific societies refuse to review, publish or present any human-editing work not pre-registered there, the same publication chokepoint that already enforces clinical-trial registration. Second, make national licensing the point of enforcement: any clinic performing embryo editing must hold a licence, and performing an unlicensed germline edit is prosecuted as a criminal offence, as China ultimately treated the He Jiankui case (CBS News, 2019). Third, cut off the money: public and major charitable funders bar grants to any institution that conducts or hosts unregistered germline work. Publication, a licence and funding are the three things a rogue researcher cannot do without, closing all three closes the ethics-shopping loophole far better than a shared statement of principles.

2. Price the cure for where the disease lives. A cure the sick cannot reach is only half a discovery. Access should be built in three tiers: outcomes-based pricing in high-income markets (payment tied to the patient actually staying crisis-free), tiered pricing scaled to national income for middle-income countries like India, and pooled or donor-backed procurement, modelled on how the Global Fund and Gavi buy vaccines and HIV medicines, for the low-income countries in sub-Saharan Africa that carry most of the global burden (The Lancet Haematology, 2023). India's National Sickle Cell Anaemia Elimination Mission already supplies the screening and patient-identification backbone such a scheme needs (National Health Mission, 2023); the missing piece is a price and a purchasing mechanism designed for that population rather than for wealthy insurers.

Conclusion

CRISPR did not arrive with instructions. It grew out of curiosity about bacteria and became, within a single decade, a tool that can cure a child of sickle cell disease, and, in the wrong hands, rewrite the human line forever. The science has now delivered its promise: a 96.7% crisis-free result and a real, approved therapy (Children's Hospital of Philadelphia / NEJM, 2024). The unfinished work is ours. If we enforce a genuine gate on heritable editing and price these cures for the sub-Saharan African and Indian communities where the disease actually falls, CRISPR closes some of the oldest gaps in medicine. If we leave both decisions to drift, the same technology deepens them. How we choose to apply this power, not whether the power exists, will shape the future of life itself.

Sources

1. BioPharma Dive (2023), FDA approves Casgevy (exa-cel) on 8 Dec 2023 as the first CRISPR medicine in the US; Vertex's $2.2M list price.
2. Children's Hospital of Philadelphia (2024), Final phase-3 exa-cel results: 29 of 30 patients (96.7%) crisis-free for ≥12 months; NEJM (Frangoul et al., 2024).
3. The Lancet Haematology / GBD 2021 (2023), ~515,000 babies born with sickle cell disease in 2021; 376,000 SCD-related deaths.
4. The Lancet Haematology / GBD 2021 (2023), 7.74 million people living with SCD globally in 2021, up 41.4% since 2000.
5. National Health Mission, India (2023), National Sickle Cell Anaemia Elimination Mission: eliminate SCD before 2047; screen 7 crore; tribal burden.
6. Lander, Baylis et al., Nature (2019), call for an international moratorium framework on clinical germline editing.
7. World Health Organization (2021), recommendations and governance framework, including a human-genome-editing registry and confidential reporting mechanism.
8. CBS News (2019), He Jiankui sentenced to three years and fined ~$430,000 for illegally creating CRISPR-edited babies.